Loading organizations...
Key people at Roboscreen GmbH.
Roboscreen GmbH develops advanced diagnostic tests and systems crucial for identifying and monitoring various diseases. The company specializes in human diagnostics, particularly focusing on the detection and quantification of viral pathogens and conducting multiparametric analyses. Their solutions integrate powerful systems that streamline every phase of analysis, encompassing automated sample preparation, robotics, and diverse detection methodologies.
The company was established in 2000 in Leipzig, Germany, born from an insight into the growing need for sophisticated diagnostic tools. Dr. Ingolf Lachmann has been a pivotal figure since the company's early days, serving as CEO and guiding its strategic development for two decades. His extensive involvement underscores the consistent focus on scientific innovation from inception.
Roboscreen's products serve the human diagnostics sector, including research institutions and clinical laboratories, enabling precise disease management. The company’s long-term vision centers on continuously advancing diagnostic capabilities through ongoing research and development, striving to enhance disease identification and patient monitoring for improved health outcomes.
Roboscreen GmbH is a Leipzig-based biotechnology company founded in 2000 that develops and manufactures in vitro diagnostic tests for viral pathogens and neurodegenerative diseases.[1][2][3] It specializes in qPCR applications, monoclonal antibodies, immunochemical tests, sample preparation kits, and ELISAs, serving clinical labs, researchers, and diagnostic facilities worldwide with certified products under DIN EN ISO 13485.[1][2][3][4] The company addresses critical needs in pathogen detection (e.g., Hepatitis viruses via RoboGene kits) and multiparametric analysis of biomarkers like Tau proteins and alpha-Synuclein for Alzheimer's and related disorders, with products including automated workflows and nucleic acid extraction kits.[2][3]
With under 25 employees and annual revenue around $5.6 million, Roboscreen maintains a focused operation post its 2005-2020 affiliation with Analytik Jena AG, continuing collaborations on automation platforms.[1][3] Its growth stems from innovative, CE-IVD compliant assays networked with global labs, emphasizing personalized diagnostics.[4]
ROBOSCREEN GmbH was established in 2000 in Leipzig, Germany, by a team of scientists and technologists expert in qPCR, monoclonal antibody production, and immunochemical test development.[1][2][3] Key principal Awad Osman leads the company, which quickly built expertise in human diagnostics for viral pathogens and neurodegenerative diseases.[3][5]
From 2005 to 2020, it operated as part of Analytik Jena AG, leveraging this period to develop its product portfolio for automated platforms like qPCR instruments—partnerships that persist today.[1][3] This integration marked a pivotal moment, enabling international recognition through research collaborations and regulatory mastery for CE-IVD market entry.[4]
Roboscreen rides the wave of precision diagnostics in infectious diseases and neurodegeneration, fueled by rising demand for early Alzheimer's detection (e.g., blood-based Tau biomarkers) and post-pandemic viral monitoring.[2][3] Timing aligns with aging populations in Europe and advances in liquid biopsy tech, where plasma enrichment kits like Neuro-IP enable non-invasive testing over CSF methods.[2]
Market forces favor it: stringent EU IVDR regulations reward ISO-certified players, while global distributor networks amplify reach amid biotech consolidation.[4] Roboscreen influences the ecosystem by pioneering multiparametric neurodegeneration panels, supporting research-to-clinic translation and collaborations that standardize viral/AD assays.[3][4]
Roboscreen is poised to expand its biomarker portfolio amid booming neurodegenerative diagnostics, potentially integrating AI-driven analysis or multiplexing for broader AD/prion panels.[2][4] Trends like blood-based neurodegeneration tests and persistent viral threats (e.g., HDV) will propel demand, especially with EU funding for personalized medicine.[3][4]
Its influence may grow through deeper automation partnerships and emerging markets, solidifying Leipzig as a diagnostics hub—echoing its foundational mission to deliver powerful, compliant systems that advance human health.[1][2]
Key people at Roboscreen GmbH.
